



Medical Information Request: ZUSDURI™ (mitomycin) for intravesical solution and cleaning and disinfecting the Chilling Block.

Thank you for your request for information regarding cleaning and disinfecting of the Chilling Block (UCB0002) used in the preparation of ZUSDURI

ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

CLEANING AND DISINFECTION INSTRUCTIONS: Clean and disinfect the Chilling Block after each use with cleaning and disinfecting agents such as PeridoxRTU® or equivalent as per your pharmacy's policy. Please refer to the full Chilling Block Instructions for Use linked [here](#).

Cleaning and Disinfecting the Chilling Block after each use:

The Chilling Block device is compatible with PeridoxRTU®, a broad-spectrum sporicidal disinfectant or equivalent*, as per your pharmacy's policy.

*Equivalent or similar agents that are compatible with the materials of the Chilling Block device include Spor-Klenz®, Oxivir®, and PREempt®.

Please follow your pharmacy's policy regarding the application of the cleaning and disinfecting agents and appropriate steps to deactivate, decontaminate, clean, and disinfect as required, for example after use with hazardous materials or before aseptic use.

Disinfection efficacy testing was performed with PeridoxRTU® in accordance to recommended manufacturer's instructions and was found acceptable for all test microorganisms.

The Chilling Block (UCB0002) contains covered stainless-steel screws and aluminum canisters, which should not rust. The canisters are anodized and should not show corrosion. There could be some staining if not dried thoroughly after cleaning or if using strong base/alkali cleaning agents.

Please refer to the Full Prescribing Information for ZUSDURI [here](#).

ZUSDURI IMPORTANT SAFETY INFORMATION:

Contraindications

ZUSDURI is contraindicated in patients with perforation of the bladder or in patients with prior hypersensitivity reactions to mitomycin or any component of the product.

Warnings and Precautions

Risks in Patients with Perforated Bladder

ZUSDURI may lead to systemic exposure to mitomycin and severe adverse reactions if administered to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised. Evaluate the bladder before the intravesical instillation of ZUSDURI and do not administer to patients with a perforated bladder or mucosal compromise until bladder integrity has been restored.

Embryo-Fetal Toxicity

Based on findings in animals and mechanism of action, ZUSDURI can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of mitomycin resulted in teratogenicity. Advise females of reproductive potential to use effective contraception during treatment with ZUSDURI and for 6 months following the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ZUSDURI and for 3 months following the last dose.

Adverse Reactions

Common Adverse Reactions

The most common ($\geq 10\%$) adverse reactions, including laboratory abnormalities, that occurred in patients treated with ZUSDURI were increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.

Additional Adverse Reactions Information

Clinically relevant adverse reactions occurring in $< 10\%$ of patients who received ZUSDURI included increased urinary frequency, fatigue, urinary incontinence, urinary retention, urethral stenosis, genital pain, urinary urgency, genital edema, genital pruritus, genital rash, urethritis, acute kidney injury, balanoposthitis, and nocturia.

Use in Specific Populations

Lactation

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ZUSDURI and for 1 week following the last dose.

Preparation and Administration Information

ZUSDURI is to be administered by intravesical instillation only. Do not administer ZUSDURI by pyelocalyceal instillation or by any other route.

ZUSDURI must be prepared and administered by a healthcare provider. To ensure proper dosing, it is important to follow the preparation instructions found in the ZUSDURI Instructions for Pharmacy and administration instructions found in the ZUSDURI Instructions for Administration.

ZUSDURI may discolor urine to a violet to blue color following the instillation procedure. Advise patients for at least 24 hours post-instillation to avoid urine contact with skin, to void urine sitting on a toilet, and to flush the toilet several times after use. Advise patients to wash hands, perineum or glans with soap and water after each instillation procedure.

ZUSDURI is a hazardous drug. Follow applicable special handling and disposal procedures.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <http://www.fda.gov/medwatch> or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please see accompanying Full Prescribing Information, Instructions for Pharmacy and Instructions for Administration.

References:

1. ZUSDURI™ (mitomycin) for intravesical solution. Prescribing Information. UroGen Pharma; 2025.
2. ZUSDURI™ (mitomycin) for intravesical solution. Instructions for Pharmacy (IFP)
3. ZUSDURI™ (mitomycin) for intravesical solution. Instructions for Administration (IFA)
4. Chilling Block (Model UCB002). Instructions for Use (IFU)
5. Data on file. UroGen Pharma.

ZUSDURI™ is a trademark and UroGen® is a registered trademark of UroGen Pharma, Ltd.
PeridoxRTU® is a trademark of CONTEC® HEALTHCARE.